九芝堂股份有限公司 2017 年第三季度报告正文 证券代码：000989 证券简称：九 芝 堂 公告编号：2017-082 九芝堂股份有限公司 2017 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 5,667,546,754.75 | 4,797,790,891.24 | | 18.13% | | 归属于上市公司股东的净资产 | 4,303,951,384.07 | | 4,136,506,541.17 | 4.05% | | （元） | | | | | | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | | | 增减 | | 年同期增减 | | 营业收入（元） | 972,828, ...

九芝堂股份有限公司 2017 年半年度报告全文 证券代码：000989 证券简称：九芝堂 公告编号：2017-052 九芝堂股份有限公司 2017 年半年度报告 2017 年 07 月 1 九芝堂股份有限公司 2017 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人李振国、主管会计工作负责人孙卫香及会计机构负责人(会计主 管人员)毛凤云声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本半年度报告涉及的未来计划、发展战略等前瞻性描述，不构成公司对投 资者的实质承诺，请投资者注意投资风险。 公司已在本报告"第四节、经营情况讨论与分析"中分析了公司未来发展可 能面临的风险因素和应对措施。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 | 2 | | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 | 5 | | 第三节 | ...

九芝堂股份有限公司 2017 年第一季度报告正文 证券代码：000989 证券简称：九 芝 堂 公告编号：2017-032 九芝堂股份有限公司 2017 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人李振国、主管会计工作负责人孙卫香及会计机构负责人(会计主 管人员)毛凤云声明：保证季度报告中财务报表的真实、准确、完整。 1 九芝堂股份有限公司 2017 年第一季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | 营业收入（元） | 684,717,265.51 | 597,800,306.20 | | 14.54% | | 归属于上市公司股东的净利润（元） | 132,976,115 ...

九芝堂股份有限公司 2016 年年度报告全文 证券代码：000989 证券简称：九芝堂 公告编号：2017-030 九芝堂股份有限公司 2016 年年度报告 2017 年 04 月 1 九芝堂股份有限公司 2016 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人李振国、主管会计工作负责人孙卫香及会计机构负责人(会计主 管人员)毛凤云声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告涉及的未来计划、发展战略等前瞻性描述，不构成公司对投资 者的实质承诺，请投资者注意投资风险。 公司已在本报告"第四节、经营情况讨论与分析"中分析了公司未来发展可 能面临的风险因素和应对措施。 公司经本次董事会审议通过的利润分配预案为：以总股本 869,354,236 股为 基数，向全体股东每 10 股派发现金红利 4.00 元（含税），送红股 0 股（含税）， 不以公积金转增股本。 2 | 目录 | | --- | | ...

Financial Performance - The company's operating revenue for 2016 was CNY 2,673,798,043.47, representing a 206.80% increase compared to CNY 871,512,680.71 in 2015[17] - The net profit attributable to shareholders for 2016 was CNY 651,809,785.10, an increase of 38.38% from CNY 471,031,522.79 in 2015[17] - The net cash flow from operating activities was CNY 612,378,390.53, which is an 80.63% increase compared to CNY 339,026,372.77 in 2015[17] - Total revenue for the fourth quarter reached ¥744,040,838.42, showing a steady increase from previous quarters[23] - Net profit attributable to shareholders for the fourth quarter was ¥188,176,939.09, reflecting a growth compared to earlier quarters[23] - The company achieved total operating revenue of CNY 2,673.80 million in 2016, an increase of 206.80% compared to the previous year[40] - The net profit attributable to the parent company was CNY 651.81 million, representing a year-on-year increase of 38.38%[40] - The pharmaceutical industry contributed ¥2,096,285,405.43, accounting for 78.40% of total revenue, with a growth of 148.00% from ¥845,265,037.94 in 2015[48] - The pharmaceutical commerce segment saw a dramatic increase in revenue to ¥566,180,335.99, representing 21.18% of total revenue, up 2,069.69% from ¥26,094,981.45 in 2015[48] Assets and Liabilities - Total assets at the end of 2016 were CNY 4,797,790,891.24, a 7.31% increase from CNY 4,470,835,279.80 at the end of 2015[18] - The net assets attributable to shareholders increased by 9.23% to CNY 4,136,506,541.17 at the end of 2016 from CNY 3,787,080,838.47 at the end of 2015[18] - Total assets included cash and cash equivalents of ¥1,557,788,227.85, representing 32.47% of total assets, an increase of 4.10% from the previous year[69] - Accounts receivable rose to ¥211,504,525.58, accounting for 4.41% of total assets, up 1.10% due to increased sales[70] Dividends and Profit Distribution - The company plans to distribute a cash dividend of CNY 4.00 per 10 shares to all shareholders[4] - In 2016, the company achieved a net profit of CNY 651.81 million, with a cash dividend distribution of CNY 347.74 million, representing 53.35% of the net profit attributable to ordinary shareholders[90] - A cash dividend of 4.00 CNY per 10 shares was proposed, totaling 347,741,694.40 CNY, which represents 100% of the total profit distribution[91] - The company’s cash dividend payout reflects its commitment to return value to shareholders while balancing development needs[91] Research and Development - R&D investment increased by 192.63% to ¥78,213,490.70 in 2016, with the number of R&D personnel rising by 374.29% to 332[62] - The company is actively developing new drug projects, including the LFG anticoagulant project and traditional Chinese medicine products, with 16 patents filed in the year[42] - The company has over 300 product approvals across various therapeutic areas, with a strong focus on cardiovascular drugs and traditional Chinese medicine[36] Market Position and Strategy - The company is positioned as a key player in the traditional Chinese medicine sector, benefiting from favorable policies aimed at promoting innovation in the industry[33] - The company has established a diverse sales model, combining self-operated and agency sales, while also exploring modern sales channels such as e-commerce[33] - The company plans to focus on health industry development, emphasizing the integration of traditional and modern medicine, and aims to enhance its brand recognition globally[79] - The company will implement a dual-engine model of "market-driven + product promotion" to foster growth in OTC drugs, prescription drugs, and health products[79] Corporate Governance and Management - The company has established independent financial departments and accounting systems to ensure financial independence[95] - The company has committed to maintaining the independence of its operations, including management and asset control[95] - The company has a clear ownership structure, ensuring that all assets are under its control[95] - The company has maintained its commitment to corporate governance with independent directors overseeing operations[171] Environmental and Social Responsibility - The company has focused on environmental protection, meeting national standards for waste disposal, wastewater treatment, and emissions control[132] - The company has actively participated in social welfare activities, including providing 1,200 boxes of cooling medicine to drivers during summer[131] - The company has engaged in community service activities, such as providing medical consultations and supporting local charitable events[130] Risks and Challenges - The pharmaceutical industry faces risks from policy changes, raw material price fluctuations, and R&D challenges, which the company plans to mitigate through proactive measures[82][83] - The company has identified potential risks and countermeasures in its future development strategy[4] Internal Controls and Audits - The audit committee reviewed the internal control system and financial information disclosure, ensuring compliance with regulations[191] - No significant internal control deficiencies were identified during the reporting period[194] - The internal control audit report confirmed effective financial reporting controls, with no major deficiencies noted[196] Employee and Management Structure - The company employed a total of 4,106 staff, with 1,289 in production, 1,577 in sales, 281 in technical roles, 115 in finance, and 844 in administration[178] - The company has established a three-tier salary system based on job nature, responsibilities, and performance, including fixed salaries, piecework pay, and commission-based pay[180] - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 3,565,100[177] Shareholder Information - The company had a total of 20,498 ordinary shareholders at the end of the reporting period[155] - The top five customers accounted for 13.82% of total sales, with the largest customer contributing ¥238,323,246.15, or 8.91% of total sales[58] - The company’s shareholding structure shows a significant reduction in state-owned shares from 19.48% to 13.64%[145]

九芝堂股份有限公司 2016 年第三季度报告正文 证券代码：000989 证券简称：九 芝 堂 公告编号：2016-069 九芝堂股份有限公司 2016 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人李振国、主管会计工作负责人孙卫香及会计机构负责人(会计主 管人员)毛凤云声明：保证季度报告中财务报表的真实、准确、完整。 1 九芝堂股份有限公司 2016 年第三季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 4,685,591,059.36 | 4,470,835,279.80 | | 4.80% | | 归属于上市公司股东的净资产（元） | 3, ...

九芝堂股份有限公司 2016 年半年度报告全文 九芝堂股份有限公司 2016 年半年度报告 公告编号：2016-047 2016 年 07 月 1 九芝堂股份有限公司 2016 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本报告的董事会会议。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 公司负责人李振国、主管会计工作负责人孙卫香及会计机构负责人(会计主 管人员)毛凤云声明：保证本半年度报告中财务报告的真实、准确、完整。 2 | 第一节 重要提示、目录和释义 2 | | --- | | 第二节 公司简介 5 | | 第三节 会计数据和财务指标摘要 7 | | 第四节 董事会报告 9 | | 第五节 重要事项 17 | | 第六节 股份变动及股东情况 24 | | 第七节 优先股相关情况 28 | | 第八节 董事、监事、高级管理人员情况 29 | | 第九节 财务报告 31 | | 第十节 备查文件目录 123 | 九芝堂 ...

九芝堂股份有限公司 2016 年第一季度报告正文 证券代码：000989 证券简称：九 芝 堂 公告编号：2016-036 九芝堂股份有限公司 2016 年第一季度报告正文 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 597,800,306.20 | 198,716,660.21 | 200.83% | | 归属于上市公司股东的净利润（元） | 131,154,991.36 | 112,175,204.74 | 16.92% | | 归属于上市公司股东的扣除非经常性损 益的净利润（元） | 126,927,195.62 | 106,286,903.37 | 19.42% | | 经营活动产生的现金流量净额（元） | 119,146,932.77 | 85,251,163.91 | 39.76% | | 基本每股收益（元/股） | 0.17 | 0.24 | -29.17% | | 稀释每股收益（元/股） | 0.17 | 0.24 ...

Financial Performance - The company's operating revenue for 2015 was CNY 871,512,680.71, representing a 9.27% increase compared to CNY 797,598,707.10 in 2014[16]. - The net profit attributable to shareholders for 2015 was CNY 471,031,522.79, which is a 16.79% increase from CNY 403,316,536.54 in 2014[16]. - The basic earnings per share for 2015 was CNY 1.03, up 17.05% from CNY 0.88 in 2014[17]. - The total assets at the end of 2015 reached CNY 4,470,835,279.80, a significant increase of 190.33% from CNY 1,539,906,365.26 at the end of 2014[17]. - The net assets attributable to shareholders at the end of 2015 were CNY 3,787,080,838.47, reflecting a 169.67% increase from CNY 1,404,326,945.74 in 2014[17]. - The net cash flow from operating activities for 2015 was CNY 339,026,372.77, a decrease of 15.17% compared to CNY 399,632,555.53 in 2014[16]. - The weighted average return on equity for 2015 was 30.10%, down from 33.08% in 2014[17]. - The company achieved total revenue of CNY 871.51 million in 2015, an increase of 9.27% year-over-year, with pharmaceutical industrial revenue reaching CNY 845.27 million, up 10.51%[41]. - The net profit attributable to the parent company was CNY 471.03 million, representing a year-over-year increase of 16.79%[41]. Dividends and Shareholder Returns - The company plans to distribute a cash dividend of CNY 4 per 10 shares to all shareholders, based on a total share capital of 755,960,206 shares[4]. - In 2015, the company distributed cash dividends totaling 302,384,082.40 yuan, which represents 64.20% of the net profit attributable to shareholders[96]. - The company plans to issue a cash dividend of 4 yuan per 10 shares and a capital reserve increase of 1.5 shares per 10 shares, increasing total share capital to 869,354,237 shares[94]. Asset Restructuring and Acquisitions - The company completed a major asset restructuring, acquiring 100% equity of Mudanjiang Youbo Pharmaceutical Co., Ltd. from nine original shareholders[8]. - The company completed a major asset restructuring by acquiring 100% equity of Youbo Pharmaceutical, enhancing its product line and market position in cardiovascular drugs[42]. - The company completed the acquisition of Mudanjiang Youbo Pharmaceutical Co., Ltd. for a total investment of RMB 6,517.8 million, holding a 100% stake[75]. - Jiuzhitang completed the acquisition of 100% equity of Youbo Pharmaceutical by issuing 458,354,938 shares to various investors, including Li Zhenguo and Harbin Institute of Technology High-tech Venture Capital Co., Ltd.[109]. Market Position and Product Development - The company has established a diverse product portfolio including over 20 second-tier products and 359 national drug registration approvals, with 37 exclusive varieties[28]. - The company is focusing on the "health and wellness" sector with its new brand "Yiban," which promotes the concept of "food and medicine sharing the same source" and includes various health products[29]. - The company has a strong market position in the OTC segment, with its "Donkey-hide gelatin" products ranking among the top in national retail sales[28]. - The company launched 15 new health products during the reporting period, including popular items like Ginseng Ejiao Tablets and Ejiao Cake[46]. - The company’s main product, Xuexitong Injection, is now covered in over 9,000 hospitals and clinics nationwide, reflecting its strong market presence[43]. Research and Development - The company applied for 42 patents in 2015, strengthening its intellectual property portfolio and innovation capabilities[46]. - Research and development investment reached ¥26,727,474.77, a 6.38% increase from the previous year, representing 3.07% of operating revenue[64]. - The company has committed to continuous R&D for strategic products and technology upgrades, actively applying for technology projects[87]. Risk Management and Compliance - The company has identified potential risk factors and corresponding countermeasures in its management discussion and analysis section[4]. - The company faces significant risks from macro policies, including slower industry growth and potential changes in pricing systems[89]. - The company emphasizes the importance of strategic raw material procurement to mitigate risks associated with supply and price fluctuations[90]. - The company has maintained a strong compliance record, reporting no penalties from regulatory bodies in the past three years[172]. Corporate Governance and Management - The company has committed to maintaining the independence of its operations and management, ensuring no interference from controlling shareholders[102]. - The company has established a framework for compliance with performance commitments, ensuring accountability among the compensation obligors[100]. - The board has established three specialized committees: the Strategy Committee, Audit Committee, and Nomination, Compensation, and Assessment Committee, which functioned effectively during the reporting period[187]. - The independent directors attended all board meetings and did not raise any objections to company matters during the reporting period[185][186]. Employee and Operational Structure - The total number of employees in the company is 3,800, with 2,034 in the parent company and 1,766 in major subsidiaries[176]. - The company has implemented a three-tiered compensation system based on job nature and responsibilities, including salary, piece-rate, and commission systems[177]. - The company has established an annual training plan to enhance employee skills through various learning methods[178]. Future Outlook and Strategic Goals - The company has set a future outlook with a revenue target of 1.8 billion yuan for the next fiscal year, indicating a projected growth of 20%[172]. - The company is expanding its market presence, targeting an increase in market share by 10% in the next year through strategic partnerships[172]. - The management has outlined a strategy to enhance operational efficiency, aiming for a 5% reduction in operational costs over the next year[172].

九芝堂股份有限公司 2015 年第三季度报告正文 证券代码：000989 证券简称：九 芝 堂 公告编号：2015-079 九芝堂股份有限公司 2015 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚 假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人张峥、主管会计工作负责人毛凤云及会计机构负责人(会计主管人员)龙晓声明：保证季度 报告中财务报表的真实、准确、完整。 1 九芝堂股份有限公司 2015 年第三季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 2,278,727,030.88 | 2,149,337,166.22 | | 6.02% | | 归属于上市公司股东的净资产（元） | 1,706 ...